Showing results (2011-2020 of 2,175) with videos related to
Sort By:
Pageof 218
Circulation|August 25, 2021
Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA)Justin A Ezekowitz, Yinggan Zheng, Alain Cohen-Solal, et al.American Heart Journal|June 4, 2018
Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysisBenjamin M Scirica, Sameer Bansilal, Farideh Davoudi, et al.Journal of the American Academy of Dermatology|June 5, 2019
Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled studyMegan H Noe, Marilyn T Wan, Daniel B Shin, et al.Journal of Thrombosis and Thrombolysis|February 7, 2012
Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trialSean van Diepen, Matthew T Roe, Renato D Lopes, et al.American Heart Journal|December 22, 2005
Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trialsJohn M Galla, Kenneth W Mahaffey, Shelly K Sapp, et al.The American Journal of Cardiology|August 18, 2014
Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial)Marco Valgimigli, Pierluigi Tricoci, Zhen Huang, et al.Heart (British Cardiac Society)|March 12, 2008
Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevationR D Lopes, K S Pieper, J R Horton, et al.The American Journal of Cardiology|March 18, 2015
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial)Jan H Cornel, Pierluigi Tricoci, Yuliya Lokhnygina, et al.European Journal of Heart Failure|March 30, 2023
Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudyBurkert Pieske, Elisabeth Pieske-Kraigher, Carolyn S P Lam, et al.Lancet (London, England)|April 12, 2001
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational studyH D Aronow, E J Topol, M T Roe, et al.Pageof 218